These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 8187370)

  • 1. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
    Farkas A; Leprán I; Papp JG
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
    Hohnloser SH; Klingenheben T; Singh BN
    Ann Intern Med; 1994 Oct; 121(7):529-35. PubMed ID: 8067651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH; van de Loo A; Baedeker F
    J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.
    Mattioni TA; Zheutlin TA; Sarmiento JJ; Parker M; Lesch M; Kehoe RF
    Ann Intern Med; 1989 Oct; 111(7):574-80. PubMed ID: 2774388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case series of sotalol-induced torsade de pointes in patients with atrial fibrillation--a tale with a twist.
    Tan HH; Hsu LF; Kam RM; Chua T; Teo WS
    Ann Acad Med Singap; 2003 May; 32(3):403-7. PubMed ID: 12854385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.
    D'Aloia A; Faggiano P; Brentana L; Boldini A; Pedrinazzi C; Procopio R; Dei Cas L
    Int J Cardiol; 2005 Dec; 105(3):337-9. PubMed ID: 15985302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia--evidence for a significant contribution of the "cardiac memory".
    Haverkamp W; Hördt M; Breithardt G; Borggrefe M
    Clin Cardiol; 1998 Jan; 21(1):55-8. PubMed ID: 9474467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
    Silvetti MS; Drago F; Bevilacqua M; Ragonese P
    Ital Heart J; 2001 Mar; 2(3):231-6. PubMed ID: 11305536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
    Yamada S; Kuga K; Yamaguchi I
    Jpn Circ J; 2001 Mar; 65(3):236-8. PubMed ID: 11266201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.